All In Biotech

Drug Trial Radar · NCT00861926

Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)

48-week, Multicentre, Multinational, Randomized, Double-blind, 2-arm Parallel Group, Comparing the Efficacy of FOSTER for Maintenance & Reliever Versus Fixed-dose FOSTER for Maintenance + Salbutamol as Reliever in Asthmatics ≥ 18 Years of Age

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,714 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,714

Actual

Start

Mar 20, 2009

Primary completion

Dec 7, 2010

Study completion Dec 7, 2010

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Mar 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: The primary objective of the study was to compare the efficacy of Maintenance and Reliever Therapy (MART) with Foster® 100/6 μg (one inhalation bid) plus additional inhalations as needed, with the standard treatment of Foster® 100/6 μg (one inhalation bid) plus salbutamol 100 μg (Ventolin ®) additional inhalations as needed in not fully controlled asthmatic patients. Secondary objectives: The secondary objectives of the study were: * to evaluate the effect of treatments on lung function parameters and on other clinical outcome measures, and * to assess the safety and the tolerability of Foster® as MART.

Conditions

  • Asthma

Interventions

  • SalbutamolDrug

    Administered via a pressurized metered-dose inhaler

  • Beclomethasone dipropionate + FormoterolDrug

    Administered via a pressurized metered-dose inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Severe Asthma ExacerbationTime frame: From First IMP dose to week 48 (EOT)
  2. Cumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)Time frame: From First dose to end of each interval: 0-4, 4-12, 12-24, 24-36, 36-48 weeks

Locations

206 sites in 14 countries. Site status is shown where the registry gives one.

  • Chiesi Site No 103

    Burgas, Bulgaria

  • Chiesi Site No 107

    Pleven, Bulgaria

  • Chiesi Site No 105

    Plovdiv, Bulgaria

  • Chiesi Site No 111

    Plovdiv, Bulgaria

  • Chiesi Site No 115

    Plovdiv, Bulgaria

  • Chiesi Site No 102

    Rousse, Bulgaria

  • Chiesi Site No 104

    Sofia, Bulgaria

  • Chiesi Site No 108

    Sofia, Bulgaria

  • Chiesi Site No 109

    Sofia, Bulgaria

  • Chiesi Site No 110

    Sofia, Bulgaria

  • Chiesi Site No 113

    Sofia, Bulgaria

  • Chiesi Site No 117

    Sofia, Bulgaria

  • Chiesi Site No 106

    Stara Zagora, Bulgaria

  • Chiesi Site No 116

    Troyan Municipality, Bulgaria

  • Chiesi Site No 0101

    Varna, Bulgaria

  • Chiesi Site No 112

    Veliko Tarnovo, Bulgaria

  • Chiesi Site No 305

    Osijek, Croatia

  • Chiesi Site No 304

    Rijeka, Croatia

  • Chiesi Site No 306

    Zadar, Croatia

  • Chiesi Site No 301

    Zagreb, Croatia

  • Chiesi Site No 302

    Zagreb, Croatia

  • Chiesi Site No 307

    Zagreb, Croatia

  • Chiesi Site No 201

    Beroun, Czechia

  • Chiesi Site No 206

    Brno, Czechia

  • Chiesi Site No 207

    Brno, Czechia

  • Chiesi Site No 202

    Prague, Czechia

  • Chiesi Site No 203

    Prague, Czechia

  • Chiesi Site No 204

    Prague, Czechia

  • Chiesi Site No 205

    Prague, Czechia

  • Chiesi Site No 208

    Prague, Czechia

  • Chiesi Site No 428

    Angoulême, France

  • Chiesi Site No 421

    Castelnau-le-Lez, France

  • Chiesi Site No 434

    Chauny, France

  • Chiesi Site No 403

    Dijon, France

  • Chiesi Site No 408

    Hyères, France

  • Chiesi Site No 424

    Marmande, France

  • Chiesi Site No 410

    Marseille, France

  • Chiesi Site No 436

    Marseille, France

  • Chiesi Site No 418

    Montpellier, France

  • Chiesi Site No 417

    Nice, France

Showing 40 of 206 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.